Valtya 1/35 Kit
Product Images NDC 70700-304

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Valtya 1/35 (NDC 70700-304). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (E76714c0 97e3 4030 Baba 0b4caf86ac34 01)

Chemical structure diagrams of the active ingredients ethynodiol diacetate and ethinyl estradiol, each labeled with its molecular weight. Ethynodiol diacetate structure shows steroid backbone with acetate group; ethinyl estradiol structure includes phenolic ring and hydroxyl groups.*

FDA Label Image

Graph (E76714c0 97e3 4030 Baba 0b4caf86ac34 02)

A bar graph showing mortality rates (number of deaths per 100,000 woman-years) across different age groups (15-24, 25-34, 35-44, 45-) for ever-users and controls of a drug, separated by smokers and non-smokers. Mortality rates increase markedly with age, especially among ever-users who smoke, compared to other groups.*

FDA Label Image

Blister (E76714c0 97e3 4030 Baba 0b4caf86ac34 03)

Blister pack of VALTYA 1/35 containing Ethynodiol Diacetate and Ethinyl Estradiol tablets, 1 mg/35 mcg strength. The pack has 28 tablets arranged in four rows for four weeks, with days of the week labeled above each tablet position. It includes light orange active tablets and green reminder pills, with storage instructions at controlled room temperature. The label indicates prescription use only.*

FDA Label Image

3s Carton (Image 01)

VALTYA 1/35 kit packaging label featuring ethynodiol diacetate and ethinyl estradiol tablets, USP. The package highlights a strength of 1 mg/35 mcg and indicates it contains 3 pouches, each with one blister pack of 28 tablets. The label shows the Xiromed LLC branding and includes usage disclaimers and NDC 70700-304.*

FDA Label Image

Figure 2. Risk Of Breast Cancer With Combined Oral Contraceptive Use (Image 03)

A forest plot showing effect estimates (OR/RR) from various studies related to women's contraceptive and hormone use. The studies are listed on the left, each with a corresponding horizontal line and dot representing the effect estimate and confidence interval. The x-axis ranges from -1.5 to 2, with a vertical line at 1 indicating no effect. The plot includes studies from 2002 to 2017.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.